A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

Clinical trial NCT05933967 · RECRUITING

Trial details

NCT number: NCT05933967
Sponsor: Shandong Cancer Hospital and Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

The First Affiliated Hospital of Nanchang University

Start date: 2023-06-01
Primary completion: 2024-12-30
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.